Drugs / ZT006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07307638 | Nov 2024 → Jun 2025 | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07230132 | Dec 2025 → Dec 2026 expected | obesity disorder | Beijing QL Biopharmaceutical Co.,Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZT006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07307638 ↗ |
| Modality | Peptide | “ZT006 is an oral, long-acting glucagon-like peptide-1.” NCT07307638 ↗ |
| Route | Oral | “administered per os, daily” NCT07230132 ↗ |